



## Information on total number of voting rights and shares composing the share capital as at October 31, 2021

**Paris, November 2nd, 2021** – 6.00PM CEST - Pixium Vision (Euronext Growth Paris - FR0011950641 - ALPIX), a bioelectronic company developing innovative bionic vision systems to allow patients who have lost their sight to lead more independent lives, announces the evolution of its share capital. The number of voting rights and shares composing its share capital as at October 31, 2021 is as follow:

Total voting rights	Total number of shares composing capital
Total real voting rights <sup>(1)</sup> : 58,387,497	58,469,860 <sup>(3)</sup>
Total theoretical voting rights <sup>(2)</sup> : 58,469,860	

*(1): The actual (or net) voting rights correspond to the total number of voting rights exercisable at General Meetings. They are calculated based on the total number of voting rights attached to the total number of shares, less any shares without voting rights (treasury shares, etc.).*

*(2): Theoretical (or gross) voting rights include all voting rights attached to the shares (including those without voting rights).*

*(3): Including 665,000 new shares in accordance with the contract of Equity Line financing cancelled on November 6, 2019; and 12,533,034 new shares from conversion of ORNAN2019 by ESGO Fund.*

## Contacts

### Pixium Vision

Offer Nonhoff  
Chief Financial Officer  
[investors@pixium-vision.com](mailto:investors@pixium-vision.com)

### Media Relations LifeSci Advisors

Sophie Baumont  
[sophie@lifesciadvisors.com](mailto:sophie@lifesciadvisors.com)  
+33 6 27 74 74 49

### Investor Relations LifeSci Advisors

Guillaume van Renterghem  
[gvanrenterghem@lifesciadvisors.com](mailto:gvanrenterghem@lifesciadvisors.com)  
+33 6 69 99 37 83

## ABOUT PIXIUM VISION

Pixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy. Pixium Vision's bionic vision systems are associated with a surgical intervention and a rehabilitation period. Prima System sub-retinal miniature photovoltaic wireless implant is in clinical testing for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners, including some of the most prestigious vision research institutions in the world, such as: Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona, University hospital in Bonn, and UPMC in Pittsburgh, PA. The company is EN ISO 13485 certified and qualifies as "Entreprise Innovante" by Bpifrance.

For more information: <http://www.pixium-vision.com/fr>

Follow us on [@PixiumVision](https://twitter.com/PixiumVision); [www.facebook.com/pixiumvision](https://www.facebook.com/pixiumvision)

[Linkedin www.linkedin.com/company/pixium-vision](https://www.linkedin.com/company/pixium-vision)



Pixium Vision is listed on Euronext Growth Paris.  
Euronext ticker: ALPIX - ISIN: FR0011950641

Pixium Vision shares are eligible for the French tax incentivized PEA-PME and FCPI investment vehicles.

Pixium Vision is included in the Euronext GROWTH ALLSHARE index

## Disclaimer

*This press release, implicitly or expressly, contains certain forward-looking statements concerning Pixium Vision and its business. Such statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, financial conditions, performance or achievements of Pixium Vision to be materially different from the results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Pixium Vision issues this press release as at this date and does not undertake to update any forward-looking statements contained herein, whether in response to new information, future events or otherwise. For a description of the risks and uncertainties that could cause the actual results, financial conditions, performance or achievements of Pixium Vision to differ from those contained in the forward-looking statements, please refer to section 3 "Risk Factors" of the Company's reference document, which was filed with the Autorité des Marchés Financiers under number D.20-0350 on 24 April 2020, and which can be viewed on the websites of the Autorité des Marchés Financiers - "AMF" ([www.amf-france.org](http://www.amf-france.org)) and Pixium Vision ([www.pixium-vision.com](http://www.pixium-vision.com)).*